Coping with space motion sickness in Spacelab missions.

Area of Science:

• Aerospace Medicine
• Neuroscience
• Pharmacology

Background:

• Approximately 75% of astronauts experience space motion sickness during their initial orbital flights.
• Current methods for preventing space motion sickness, such as pre-flight adaptation and crew selection, are not practical.
• Developing effective countermeasures is essential for astronaut health and mission success.

Purpose of the Study:

• To evaluate the efficacy and side effect profile of transdermal therapeutic system (TTS)-scopolamine for space motion sickness prevention.
• To explore novel anti-motion sickness remedies and synergistic drug combinations.

Main Methods:

• Systematic evaluation of existing claims regarding TTS-scopolamine's potency and low side effects.
• Investigation of new pharmaceutical agents and drug combinations for motion sickness.

Main Results:

• Transdermal scopolamine patches deliver medication over three days, offering a potential preventative strategy.
• Ongoing research aims to validate the high potency and low side effect claims of TTS-scopolamine.
• New antimotion sickness remedies and drug combinations are under active investigation.

Conclusions:

• Transdermal scopolamine presents a viable option for widespread preventative medication against space motion sickness.
• Further research is necessary to confirm the effectiveness and safety of TTS-scopolamine and other novel treatments.
• Developing practical and effective solutions for space motion sickness is critical for future space exploration.